Prostate Specific Antigen Density for Biopsy Triage in a Low Resource Setting: An Exploratory Real World Evaluation in a Late Presenting Cohort
SN Comprehensive Clinical Medicine · 17.10.2026 · 8 (1)
DOI: 10.1007/s42399-026-02783-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 17.10.2026. Verfasst von Wajahat Ali und 7 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Purpose
To evaluate the diagnostic performance of prostate-specific antigen density (PSAD) compared with PSA for biopsy triage and explore the potential clinical impact of different PSAD thresholds in a symptomatic, late-presenting cohort in a low-resource setting.
Methods
This retrospective observational study included consecutive adult men undergoing transrectal ultrasound guided prostate biopsy at a tertiary referral center in Pakistan from August 2022 to August 2025. PSA and prostate volume were obtained from routine clinical data. PSAD was calculated as PSA divided by prostate volume. The primary outcome was histopathologically confirmed prostate cancer. Exploratory threshold analyses evaluated PSAD cutoffs of 0.07, 0.10, and 0.15 ng/mL/mL and PSA cutoffs of 4, 10, and 20 ng/mL. Additional exploratory analyses evaluated PSAD performance within PSA < 10 and 10 to 20 ng/mL strata.
Results
Among 55 eligible men, the cancer detection rate was 47.3% (26/55), with 84.6% (22/26) being Grade Group ≥ 3 disease. The cohort presented with high median PSA (19.0 ng/mL) and large median prostate volume (76.6 mL). PSAD demonstrated comparable discriminative ability to PSA (AUC: 0.767 vs. 0.774, p = 0.89). Across the overall cohort, increasing the PSAD threshold from ≥ 0.07 to ≥ 0.15 ng/mL/mL increased biopsy avoidance from 7.3% to 21.8%. PSAD ≥ 0.07 missed one cancer and no Grade Group ≥ 3 disease, whereas PSAD ≥ 0.10 and ≥ 0.15 each missed two cancers, including one Grade Group 5 cancer. In the exploratory PSA 10 to 20 ng/mL subgroup ( n = 19), PSAD ≥ 0.15 would have avoided 5/19 biopsies (26.3%) while detecting 5/6 cancers; the single missed cancer was Grade Group 2, with no Grade Group ≥ 3 cancers missed.
Conclusions
In this small, highly selected symptomatic biopsy referred cohort, PSAD did not demonstrate superior overall discrimination to PSA. Instead, exploratory analyses suggested that its potential clinical utility depends on both the selected PSAD threshold and baseline PSA range. The most promising signal was observed among men with PSA 10 to 20 ng/mL, although the small number of events precludes identification of an optimal or clinically validated threshold. These findings are hypothesis generating and support prospective validation in larger cohorts.
Zitieren
APA
Ali, W., Shahzil, M., Zaidi, A. I., Sheraz, A., Asif, A., Ullah, M. S., Asghar, M. R., & Ahmad, I. (2026). Prostate Specific Antigen Density for Biopsy Triage in a Low Resource Setting: An Exploratory Real World Evaluation in a Late Presenting Cohort. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02783-0
Vancouver
Ali W, Shahzil M, Zaidi AI, Sheraz A, Asif A, Ullah MS, et al. Prostate Specific Antigen Density for Biopsy Triage in a Low Resource Setting: An Exploratory Real World Evaluation in a Late Presenting Cohort. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02783-0
BibTeX
@article{Ali2026,
author = {Ali, Wajahat and Shahzil, Muhammad and Zaidi, Ali Imran and Sheraz, Ahmed and Asif, Amna and Ullah, Muhammad Sami and Asghar, Muhammad Rashid and Ahmad, Imtisal},
title = {Prostate Specific Antigen Density for Biopsy Triage in a Low Resource Setting: An Exploratory Real World Evaluation in a Late Presenting Cohort},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02783-0}
}
EUVIMED